Literature DB >> 24975478

Getting Syk: spleen tyrosine kinase as a therapeutic target.

Robert L Geahlen1.   

Abstract

Spleen tyrosine kinase (Syk) is a cytoplasmic protein tyrosine kinase well known for its ability to couple immune cell receptors to intracellular signaling pathways that regulate cellular responses to extracellular antigens and antigen-immunoglobulin (Ig) complexes of particular importance to the initiation of inflammatory responses. Thus, Syk is an attractive target for therapeutic kinase inhibitors designed to ameliorate the symptoms and consequences of acute and chronic inflammation. Its more recently recognized role as a promoter of cell survival in numerous cancer cell types ranging from leukemia to retinoblastoma has attracted considerable interest as a target for a new generation of anticancer drugs. This review discusses the biological processes in which Syk participates that have made this kinase such a compelling drug target.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  allergic asthma; fostamatinib; leukemia; protein kinase inhibitor; rheumatoid arthritis; tyrosine phosphorylation

Mesh:

Substances:

Year:  2014        PMID: 24975478      PMCID: PMC4119858          DOI: 10.1016/j.tips.2014.05.007

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  108 in total

1.  R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.

Authors:  Sylvia Braselmann; Vanessa Taylor; Haoran Zhao; Su Wang; Catherine Sylvain; Muhammad Baluom; Kunbin Qu; Ellen Herlaar; Angela Lau; Chi Young; Brian R Wong; Scott Lovell; Thomas Sun; Gary Park; Ankush Argade; Stipo Jurcevic; Polly Pine; Rajinder Singh; Elliott B Grossbard; Donald G Payan; Esteban S Masuda
Journal:  J Pharmacol Exp Ther       Date:  2006-08-31       Impact factor: 4.030

2.  An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment.

Authors:  Eli O Meltzer; Robert B Berkowitz; Elliott B Grossbard
Journal:  J Allergy Clin Immunol       Date:  2005-04       Impact factor: 10.793

3.  The human and mouse complement of SH2 domain proteins-establishing the boundaries of phosphotyrosine signaling.

Authors:  Bernard A Liu; Karl Jablonowski; Monica Raina; Michael Arcé; Tony Pawson; Piers D Nash
Journal:  Mol Cell       Date:  2006-06-23       Impact factor: 17.970

4.  Protein-tyrosine kinase Syk is required for pathogen engulfment in complement-mediated phagocytosis.

Authors:  Yuhong Shi; Yumi Tohyama; Tomomi Kadono; Jinsong He; S M Shahjahan Miah; Ryoichi Hazama; Chisato Tanaka; Kaoru Tohyama; Hirohei Yamamura
Journal:  Blood       Date:  2006-01-31       Impact factor: 22.113

Review 5.  ITAM-mediated tonic signalling through pre-BCR and BCR complexes.

Authors:  John G Monroe
Journal:  Nat Rev Immunol       Date:  2006-04       Impact factor: 53.106

6.  Syk is required for monocyte/macrophage chemotaxis to CX3CL1 (Fractalkine).

Authors:  Jean-Claude Gevrey; Beth M Isaac; Dianne Cox
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

7.  A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes.

Authors:  Hoon-Suk Cha; David L Boyle; Tomoyuki Inoue; Reineke Schoot; Paul P Tak; Polly Pine; Gary S Firestein
Journal:  J Pharmacol Exp Ther       Date:  2006-02-01       Impact factor: 4.030

8.  Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma.

Authors:  Andrea Rinaldi; Ivo Kwee; Monica Taborelli; Cristina Largo; Silvia Uccella; Vittoria Martin; Giulia Poretti; Gianluca Gaidano; Giuseppe Calabrese; Giovanni Martinelli; Luca Baldini; Giancarlo Pruneri; Carlo Capella; Emanuele Zucca; Finbarr E Cotter; Juan C Cigudosa; Carlo V Catapano; Maria G Tibiletti; Francesco Bertoni
Journal:  Br J Haematol       Date:  2006-02       Impact factor: 6.998

Review 9.  The Syk tyrosine kinase: a new negative regulator in tumor growth and progression.

Authors:  Peter J Coopman; Susette C Mueller
Journal:  Cancer Lett       Date:  2006-01-27       Impact factor: 8.679

10.  MMTV Env encodes an ITAM responsible for transformation of mammary epithelial cells in three-dimensional culture.

Authors:  Elad Katz; Mohamed H Lareef; John C Rassa; Shannon M Grande; Leslie B King; Jose Russo; Susan R Ross; John G Monroe
Journal:  J Exp Med       Date:  2005-01-31       Impact factor: 14.307

View more
  79 in total

1.  A genetic stochastic process model for genome-wide joint analysis of biomarker dynamics and disease susceptibility with longitudinal data.

Authors:  Liang He; Ilya Zhbannikov; Konstantin G Arbeev; Anatoliy I Yashin; Alexander M Kulminski
Journal:  Genet Epidemiol       Date:  2017-06-21       Impact factor: 2.135

2.  Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity.

Authors:  Yaron Carmi; Tyler R Prestwood; Matthew H Spitzer; Ian L Linde; Jonathan Chabon; Nathan E Reticker-Flynn; Nupur Bhattacharya; Hong Zhang; Xiangyue Zhang; Pamela A Basto; Bryan M Burt; Michael N Alonso; Edgar G Engleman
Journal:  JCI Insight       Date:  2016-11-03

3.  Entropic allostery dominates the phosphorylation-dependent regulation of Syk tyrosine kinase release from immunoreceptor tyrosine-based activation motifs.

Authors:  Chao Feng; Amitava Roy; Carol Beth Post
Journal:  Protein Sci       Date:  2018-10-02       Impact factor: 6.725

4.  A reevaluation of the spleen tyrosine kinase (SYK) activation mechanism.

Authors:  My S Mansueto; Abigail Reens; Larissa Rakhilina; An Chi; Bo-Sheng Pan; J Richard Miller
Journal:  J Biol Chem       Date:  2019-03-28       Impact factor: 5.157

5.  Syk interacts with and phosphorylates nucleolin to stabilize Bcl-x(L) mRNA and promote cell survival.

Authors:  Wen-Horng Wang; Michael O Childress; Robert L Geahlen
Journal:  Mol Cell Biol       Date:  2014-08-04       Impact factor: 4.272

6.  Alveolar Bone Protection by Targeting the SH3BP2-SYK Axis in Osteoclasts.

Authors:  Mizuho Kittaka; Tetsuya Yoshimoto; Collin Schlosser; Robert Rottapel; Mikihito Kajiya; Hidemi Kurihara; Ernst J Reichenberger; Yasuyoshi Ueki
Journal:  J Bone Miner Res       Date:  2019-10-24       Impact factor: 6.741

7.  A respiratory chain controlled signal transduction cascade in the mitochondrial intermembrane space mediates hydrogen peroxide signaling.

Authors:  Heide Christine Patterson; Carolin Gerbeth; Prathapan Thiru; Nora F Vögtle; Marko Knoll; Aliakbar Shahsafaei; Kaitlin E Samocha; Cher X Huang; Mark Michael Harden; Rui Song; Cynthia Chen; Jennifer Kao; Jiahai Shi; Wendy Salmon; Yoav D Shaul; Matthew P Stokes; Jeffrey C Silva; George W Bell; Daniel G MacArthur; Jürgen Ruland; Chris Meisinger; Harvey F Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-05       Impact factor: 11.205

Review 8.  Novel Therapies in Acute Lymphoblastic Leukemia.

Authors:  Kathleen W Phelan; Anjali S Advani
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

Review 9.  Recent advances and novel treatment paradigms in acute lymphocytic leukemia.

Authors:  Nikolaos Papadantonakis; Anjali S Advani
Journal:  Ther Adv Hematol       Date:  2016-06-29

10.  SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.

Authors:  Jonathan C Poe; Wei Jia; Julie A Di Paolo; Nancy J Reyes; Ji Yun Kim; Hsuan Su; John S Sundy; Adela R Cardones; Victor L Perez; Benny J Chen; Nelson J Chao; Diana M Cardona; Daniel R Saban; Stefanie Sarantopoulos
Journal:  JCI Insight       Date:  2018-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.